p>
Weighted average common shares
outstanding - basic and diluted 43,629,975 40,914,902
Selected Condensed Consolidated June 30, December 31,
Balance Sheet Data 2008 2007
(Unaudited) (Audited)
Cash and cash equivalents $4,138,989 $7,722,816
Accounts receivable, net 406,963 565,613
Inventories, net 1,741,439 1,037,164
Prepaid expenses and other current assets 537,124 522,067
Property and equipment, net 2,006,735 1,650,632
Patented technology and
intangibles, net 4,371,502 4,766,330
Other long-term assets 600,041 661,067
Total assets $13,802,793 $16,925,689
Current liabilities $9,602,428 $5,255,392
Long-term liabilities 96,420 3,241,992
Stockholder's equity 4,103,945 8,428,305
Total liabilities and
stockholder's equity $13,802,793 $16,925,689
'/>"/>SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities2.
Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack3.
Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.4.
Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling5.
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates6.
Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant7.
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C8.
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE9.
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting10.
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study11.
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines